Identification of molecular markers for pre-engraftment immune reactions after cord blood transplantation by SELDI-TOF MS

Bone Marrow Transplantation

Volumn 45, Issue 11, 2010, Pages 1594-1601

  Morita Hoshi, Y ^a   Mori, S I ^a   Soeda, A ^a   Wakeda, T ^a   Ohsaki, Y ^b   Shiwa, M ^b   Masuoka, K ^c   Wake, A ^c   Taniguchi, S ^c   Takaue, Y ^a   Heike, Y ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b Bio Rad Laboratories KK   (Japan)

^c TORANOMON HOSPITAL   (Japan)

Author keywords

cord blood transplantation; pre engraftment immune reactions; SELDI TOF MS; serum amyloid A

Indexed keywords

AMYLOID A PROTEIN; ANAPHYLATOXIN; ANAPHYLATOXIN C4A; ANTIBIOTIC AGENT; BUSULFAN; CORTICOSTEROID; CYCLOSPORIN A; FLUDARABINE; MELPHALAN; METHOTREXATE; MOLECULAR MARKER; TACROLIMUS; UNCLASSIFIED DRUG;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; AGED; ANION EXCHANGE; ARTICLE; CONTROLLED STUDY; CORD BLOOD STEM CELL TRANSPLANTATION; ENGRAFTMENT SYNDROME; FEMALE; FINGER DERMATOGLYPHICS; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERACUTE GRAFT VERSUS HOST DISEASE; IMMUNOPATHOLOGY; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MYELOFIBROSIS; PERIPHERAL T CELL LYMPHOMA; POLYACRYLAMIDE GEL ELECTROPHORESIS; PREENGRAFTMENT IMMUNE REACTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEOMICS; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; T CELL LEUKEMIA; WHOLE BODY RADIATION;

ADULT; AGED; BIOLOGICAL MARKERS; BLOOD PROTEINS; CORD BLOOD STEM CELL TRANSPLANTATION; FEMALE; GRAFT VS HOST DISEASE; HUMANS; MALE; MIDDLE AGED; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 78149471112     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2010.18     Document Type: Article

References (34)

1. Kishi Y, Kami M, Miyakoshi S, Kanda Y, Murashige N, Teshima T et al. Early immune reaction after reduced-intensity cord-blood transplantation for adult patients. Transplantation 2005; 80: 34-40. (Pubitemid 40980892)
2. Miyakoshi S, Yuji K, Kami M, Kusumi E, Kishi Y, Kobayashi K et al. Successful engraftment after reduced-intensity umbilical cord blood transplantation for adult patients with advanced hematological diseases. Clin Cancer Res 2004; 10: 3586-3592. (Pubitemid 38697591)
3. Uchida N, Wake A, Takagi S, Yamamoto H, Kato D, Matsuhashi Y et al. Umbilical cord blood transplantation after reduced-intensity conditioning for elderly patients with hematologic diseases. Biol Blood Marrow Transplant 2008; 14: 583-590. (Pubitemid 351494752)
4. Takahashi S, Iseki T, Ooi J, Tomonari A, Takasugi K, Shimohakamada Y et al. Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematologic malignan-cies. Blood 2004; 104: 3813-3820. (Pubitemid 39564462)
5. Narimatsu H, Terakura S, Matsuo K, Oba T, Uchida T, Iida H et al. Short-term methotrexate could reduce early immune reactions and improve outcomes in umbilical cord blood transplantation for adults. Bone Marrow Transplant 2007; 39: 31-39. (Pubitemid 44921652)
6. Mori T, Aisa Y, Nakazato T, Yamazaki R, Shimizu T, Mihara A et al. Tacrolimus and methotrexate for the prophylaxis of graft-versus-host disease after unrelated donor cord blood transplantation for adult patients with hematologic malignan-cies. Transplant Proc 2007; 39: 1615-1619. (Pubitemid 46907941)
7. Heike Y, Hosokawa M, Osumi S, Fujii D, Aogi K, Takigawa N et al. Identification of serum proteins related to adverse effects induced by docetaxel infusion from protein expression profiles of serum using SELDI ProteinChip system. Anticancer Res 2005; 25: 1197-1203. (Pubitemid 40546790)
8. Srinivasan R, Daniels J, Fusaro V, Lundqvist A, Killian JK, Geho D et al. Accurate diagnosis of acute graft-versus-host disease using serum proteomic pattern analysis. Exp Hematol 2006; 34: 796-801. (Pubitemid 43737094)
9. Weissinger EM, Mischak H, Ganser A, Hertenstein B. Value of proteomics applied to the follow-up in stem cell transplan-tation. Ann Hematol 2006; 85: 205-211. (Pubitemid 43298665)
10. Kaiser T, Kamal H, Rank A, Kolb HJ, Holler E, Ganser A et al. Proteomics applied to the clinical follow-up of patients after allogeneic hematopoietic stem cell transplantation. Blood 2004; 104: 340-349. (Pubitemid 38900013)
11. Weissinger EM, Schiffer E, Hertenstein B, Ferrara JL, Holler E, Stadler M et al. Proteomic patterns predict acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood 2007; 109: 5511-5519. (Pubitemid 46890577)
12. El Essawy B, Otu HH, Choy B, Zheng XX, Libermann TA, Strom TB. Proteomic analysis of the allograft response. Transplantation 2006; 82: 267-274. (Pubitemid 44126825)
13. Yamayoshi Y, Watanabe T, Tanabe M, Hoshino K, Matsu-moto K, Morikawa Y et al. Novel application of ProteinChip technology exploring acute rejection markers of rat small bowel transplantation. Transplantation 2006; 82: 320-326. (Pubitemid 44223029)
14. Albitar M, Potts SJ, Giles FJ, O'Brien S, Keating M, Thomas D et al. Proteomic-based prediction of clinical behavior in adult acute lymphoblastic leukemia. Cancer 2006; 106: 1587-1594.
15. Koopmann J, Zhang Z, White N, Rosenzweig J, Fedarko N, Jagannath S et al. Serum diagnosis of pancreatic adenocarci-noma using surface-enhanced laser desorption and ionization mass spectrometry. Clin Cancer Res 2004; 10: 860-868. (Pubitemid 38198884)
16. Wong YF, Cheung TH, Lo KW, Wang VW, Chan CS, Ng TB et al. Protein profiling of cervical cancer by protein-biochips: proteomic scoring to discriminate cervical cancer from normal cervix. Cancer Lett 2004; 211: 227-234.
17. Yang SY, Xiao XY, Zhang WG, Zhang LJ, Zhang W, Zhou B et al. Application of serum SELDI proteomic patterns in diagnosis of lung cancer. BMC Cancer 2005; 5: 83. (Pubitemid 41461050)
18. Ward DG, Suggett N, Cheng Y, Wei W, Johnson H, Billingham LJ et al. Identification of serum biomarkers for colon cancer by proteomic analysis. Br J Cancer 2006; 94: 1898-1905. (Pubitemid 43882582)
19. Malik G, Ward MD, Gupta SK, Trosset MW, Grizzle WE, Adam BL et al. Serum levels of an isoform of apolipoprotein A-II as a potential marker for prostate cancer. Clin Cancer Res 2005; 11: 1073-1085. (Pubitemid 40175756)
20. Tolson J, Bogumil R, Brunst E, Beck H, Elsner R, Humeny A et al. Serum protein profiling by SELDI mass spectrometry: detection of multiple variants of serum amyloid alpha in renal cancer patients. Lab Invest 2004; 84: 845-856. (Pubitemid 38833244)
21. Le L, Chi K, Tyldesley S, Flibotte S, Diamond DL, Kuzyk MA et al. Identification of serum amyloid A as a biomarker to distinguish prostate cancer patients with bone lesions. Clin Chem 2005; 51: 695-707. (Pubitemid 40463921)
22. Niemi K, Baumann MH, Kovanen PT, Eklund KK. Serum amyloid A (SAA) activates human mast cells which leads into degradation of SAA and generation of an amyloidogenic SAA fragment. Biochim Biophys Acta 2006; 1762: 424-430. (Pubitemid 43344303)
23. Uhlar CM, Whitehead AS. Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem 1999; 265: 501-523.
24. Salazar A, Pinto X, Mana J. Serum amyloid A and high-density lipoprotein cholesterol: serum markers of inflammation in sarcoidosis and other systemic disorders. Eur J Clin Invest 2001; 31: 1070-1077. (Pubitemid 36216616)
25. Katayama T, Nakashima H, Takagi C, Honda Y, Suzuki S, Iwasaki Y et al. Serum amyloid a protein as a predictor of cardiac rupture in acute myocardial infarction patients following primary coronary angioplasty. Circ J 2006; 70: 530-535.
26. Katayama T, Nakashima H, Honda Y, Suzuki S, Yamamoto T, Iwasaki Y et al. The relationship between acute phase serum amyloid A (SAA) protein concentrations and left ventricular systolic function in acute myocardial infarction patients treated with primary coronary angioplasty. Int Heart J 2007; 48: 45-55. (Pubitemid 46522732)
27. Muller TF, Trosch F, Ebel H, Grussner RW, Feiber H, Goke B et al. Pancreas-specific protein (PASP), serum amyloid A (SAA), and neopterin (NEOP) in the diagnosis of rejection after simultaneous pancreas and kidney transplantation. TransplInt 1997; 10: 185-191. (Pubitemid 27174071)
28. Maury CP, Teppo AM, Ahonen J, von Willebrand E. Measurement of serum amyloid A protein concentrations as test of renal allograft rejection in patients with initially non-functioning grafts. Br MedJ (Clin Res Ed) 1984; 288: 360-361. (Pubitemid 14113677)
29. Hartmann A, Eide TC, Fauchald P, Bentdal O, Herbert J, Gallimore JR et al. Serum amyloid A protein is a clinically useful indicator of acute renal allograft rejection. Nephrol Dial Transplant 1997; 12: 161-166. (Pubitemid 27046221)
30. Fukuda Y, Hoshino S, Tanaka I, Yoneya T, Takeshita T, Sumimoto R et al. Examination of serum amyloid A protein in kidney transplant patients. Transplant Proc 2000; 32: 1796-1798.
31. Feussner G, Stech C, Dobmeyer J, Schaefer H, Otto G, Ziegler R. Serum amyloid A protein (SAA): a marker for liver allograft rejection in humans. Clin Investig 1994; 72: 1007-1011.
32. Muller TF, Vogl M, Neumann MC, Lange H, Grimm M, Muller MM. Noninvasive monitoring using serum amyloid A and serum neopterin in cardiac transplantation. Clin Chim Acta 1998; 276: 63-74. (Pubitemid 28386829)
33. Vermes E, Kirsch M, Farrokhi T, Loisance D, Fanen P, Zimmermann R. Serum amyloid A protein: not a relevant marker for recognition of cardiac allograft rejection. Trans-plantation 2004; 78: 950-951. (Pubitemid 39298547)
34. Fuji S, Kim SW, Fukuda T, Mori S, Yamasaki S, Morita-Hoshi Y et al. Preengraftment serum C-reactive protein (CRP) value may predict acute graft-versus-host disease and nonrelapse mortality after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2008; 14: 510-517. (Pubitemid 351494745)